A rationale for the design of cell-specific toxic agents: the mechanism of action of 6-hydroxydopamine.
Rotman
A
A
National Institute of Arthritis, Metabolism and Digestive Diseases, National Institutes of Health, Bethesda. Maryland 20014, USA.
Creveling
C R
CR
D000818:Animals; D001692:Biological Transport / Q000187:drug effects; D006801:Humans; D009474:Neurons / Q000378:metabolism*; D010084:Oxidation-Reduction / Q000187:drug effects; D016627:Oxidopamine / Q000494:pharmacology / Q000633:toxicity*; D013565:Sympatholytics / Q000494:pharmacology / Q000633:toxicity*
D013565:Sympatholytics; D016627:Oxidopamine